BACKGROUND: Colorectal cancer (CRC) metastasectomy improves survival, however most patient develop recurrences. Circulating tumor cells (CTCs) are an independent prognostic marker in stage IV CRC. We hypothesized that CTCs can be enriched during metastasectomy applying different isolation techniques. METHODS: 25 CRC patients undergoing liver (16 (64%)) or lung (9 (36%)) metastasectomy were prospectively enrolled (clinicaltrial.gov identifier: NCT01722903). Central venous (liver) or radial artery (lung) tumor outflow blood (7.5 ml) was collected at incision, during resection, 30 min after resection, and on postoperative day (POD) 1. CTCs were quantified with 1. EpCAM-based CellSearch® system and 2. size-based isolation with a novel filter device (FMSA). CTCs were immunohistochemically identified using CellSearch®'s criteria (cytokeratin 8/18/19+, CD45- cells containing a nucleus (DAPI+)). CTCs were also enriched with a centrifugation technique (OncoQuick®). RESULTS: CTC numbers peaked during the resection with the FMSA in contrast to CellSearch® (mean CTC number during resection: FMSA: 22.56 (SEM 7.48) (p = 0.0281), CellSearch®: 0.87 (SEM ± 0.44) (p = 0.3018)). Comparing the 2 techniques, CTC quantity was significantly higher with the FMSA device (range 0-101) than CellSearch® (range 0-9) at each of the 4 time points examined (P < 0.05). Immunofluorescence staining of cultured CTCs revealed that CTCs have a combined epithelial (CK8/18/19) and macrophage (CD45/CD14) phenotype. CONCLUSIONS: Blood sampling during CRC metastasis resection is an opportunity to increase CTC capture efficiency. CTC isolation with the FMSA yields more CTCs than the CellSearch® system. Future studies should focus on characterization of single CTCs to identify targets for molecular therapy and immune escape mechanisms of cancer cells.
BACKGROUND:Colorectal cancer (CRC) metastasectomy improves survival, however most patient develop recurrences. Circulating tumor cells (CTCs) are an independent prognostic marker in stage IV CRC. We hypothesized that CTCs can be enriched during metastasectomy applying different isolation techniques. METHODS: 25 CRC patients undergoing liver (16 (64%)) or lung (9 (36%)) metastasectomy were prospectively enrolled (clinicaltrial.gov identifier: NCT01722903). Central venous (liver) or radial artery (lung) tumor outflow blood (7.5 ml) was collected at incision, during resection, 30 min after resection, and on postoperative day (POD) 1. CTCs were quantified with 1. EpCAM-based CellSearch® system and 2. size-based isolation with a novel filter device (FMSA). CTCs were immunohistochemically identified using CellSearch®'s criteria (cytokeratin 8/18/19+, CD45- cells containing a nucleus (DAPI+)). CTCs were also enriched with a centrifugation technique (OncoQuick®). RESULTS: CTC numbers peaked during the resection with the FMSA in contrast to CellSearch® (mean CTC number during resection: FMSA: 22.56 (SEM 7.48) (p = 0.0281), CellSearch®: 0.87 (SEM ± 0.44) (p = 0.3018)). Comparing the 2 techniques, CTC quantity was significantly higher with the FMSA device (range 0-101) than CellSearch® (range 0-9) at each of the 4 time points examined (P < 0.05). Immunofluorescence staining of cultured CTCs revealed that CTCs have a combined epithelial (CK8/18/19) and macrophage (CD45/CD14) phenotype. CONCLUSIONS: Blood sampling during CRC metastasis resection is an opportunity to increase CTC capture efficiency. CTC isolation with the FMSA yields more CTCs than the CellSearch® system. Future studies should focus on characterization of single CTCs to identify targets for molecular therapy and immune escape mechanisms of cancer cells.
Authors: Henry K Lin; Siyang Zheng; Anthony J Williams; Marija Balic; Susan Groshen; Howard I Scher; Martin Fleisher; Walter Stadler; Ram H Datar; Yu-Chong Tai; Richard J Cote Journal: Clin Cancer Res Date: 2010-09-28 Impact factor: 12.531
Authors: Long R Jiao; Christos Apostolopoulos; Jimmy Jacob; Richard Szydlo; Natalia Johnson; Nicole Tsim; Nagy A Habib; R Charles Coombes; Justin Stebbing Journal: J Clin Oncol Date: 2009-11-02 Impact factor: 44.544
Authors: R Broll; K Lembcke; C Stock; M Zingler; M Duchrow; H Schimmelpenning; M Strik; G Muller; P Kujath; H P Bruch Journal: Langenbecks Arch Chir Date: 1996
Authors: Michal Mego; Ugo De Giorgi; Shahenaah Dawood; Xuemei Wang; Vicente Valero; Eleni Andreopoulou; Beverly Handy; Naoto T Ueno; James M Reuben; Massimo Cristofanilli Journal: Int J Cancer Date: 2010-11-28 Impact factor: 7.396
Authors: Evi S Lianidou; Dimitris Mavroudis; Georgia Sotiropoulou; Sophia Agelaki; Klaus Pantel Journal: Breast Cancer Res Date: 2010-07-23 Impact factor: 6.466
Authors: Lixin Zhang; Lon D Ridgway; Michael D Wetzel; Jason Ngo; Wei Yin; Disha Kumar; Jerry C Goodman; Morris D Groves; Dario Marchetti Journal: Sci Transl Med Date: 2013-04-10 Impact factor: 17.956
Authors: Johann S de Bono; Howard I Scher; R Bruce Montgomery; Christopher Parker; M Craig Miller; Henk Tissing; Gerald V Doyle; Leon W W M Terstappen; Kenneth J Pienta; Derek Raghavan Journal: Clin Cancer Res Date: 2008-10-01 Impact factor: 12.531
Authors: Jussuf T Kaifi; Miriam Kunkel; David T Dicker; Jamal Joude; Joshua E Allen; Avisnata Das; Junjia Zhu; Zhaohai Yang; Nabeel E Sarwani; Guangfu Li; Kevin F Staveley-O'Carroll; Wafik S El-Deiry Journal: Cancer Biol Ther Date: 2015 Impact factor: 4.742
Authors: Birte Kulemann; Andrew S Liss; Andrew L Warshaw; Sindy Seifert; Peter Bronsert; Torben Glatz; Martha B Pitman; Jens Hoeppner Journal: Tumour Biol Date: 2015-12-18
Authors: Matthew W Rosenbaum; Christy E Cauley; Birte Kulemann; Andrew S Liss; Carlos Fernandez-Del Castillo; Andrew L Warshaw; Keith D Lillemoe; Sarah P Thayer; Martha B Pitman Journal: Cancer Cytopathol Date: 2017-03-03 Impact factor: 5.284
Authors: Jussuf T Kaifi; Guangfu Li; Gary Clawson; Eric T Kimchi; Kevin F Staveley-O'Carroll Journal: Cancer Biol Ther Date: 2016-04-05 Impact factor: 4.742